The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Category

Sub-category

Conference

Treatment options for high risk relapsed/refractory multiple myeloma

Dr James Berenson - Oncotherapeutics, West Hollywood, USA

$Treatment options for high risk relapsed/refractory multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )$

BCMA: A new biomarker for multiple myeloma

Dr James Berenson - Oncotherapeutics, West Hollywood, USA

BCMA: A new biomarker for multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )

ICARIA: Isatuximab, pomalidomide and dexamethasone in relapsed/refractory multip...

Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia

$ICARIA: Isatuximab, pomalidomide and dexamethasone in relapsed/refractory multiple myeloma ( Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia )$

BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed/re...

Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia

$BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed/refractory multiple myeloma ( Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia )$

Transitioning from bortezomib to ixazomib in patients with multiple myeloma

Dr Habte Yimer - Texas Oncology, Tyler, USA

Transitioning from bortezomib to ixazomib in patients with multiple myeloma ( Dr Habte Yimer - Texas Oncology, Tyler, USA )

Implementing national cancer control plans

Dr Eduardo Cazap and Dr Lisa Stevens

Implementing national cancer control plans ( Dr Eduardo Cazap and Dr Lisa Stevens )

Chemoimmunotherapy or BTK inhibition for patients with CLL

Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany

Chemoimmunotherapy or BTK inhibition for patients with CLL ( Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany )

MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma

Dr Johannes Düll - University of Würzburg, Würzburg, Germany

MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma ( Dr Johannes Düll - University of Würzburg, Würzburg, Germany )

Blinatumomab for relapsed/refractory Burkitt's lymphoma

Dr Johannes Düll - University of Würzburg, Würzburg, Germany

$Blinatumomab for relapsed/refractory Burkitt's lymphoma ( Dr Johannes Düll - University of Würzburg, Würzburg, Germany )$

Using bioinformatics and genomics to treat AML

Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany

Using bioinformatics and genomics to treat AML ( Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany )

The changing landscape of AML

Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany

The changing landscape of AML ( Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany )

CLL14: A chemotherapy-free regimen of venetoclax plus obinutuzumab for CLL

Dr Othman Al-Sawaf - Univesity of Cologne, Cologne, Germany

CLL14: A chemotherapy-free regimen of venetoclax plus obinutuzumab for CLL ( Dr Othman Al-Sawaf - Univesity of Cologne, Cologne, Germany )

More from ecancer